Molecular determinants for amyloid fibril formation: Lessons from lung surfactant protein C

Swiss Medical Weekly

Volumn 133, Issue 19-20, 2003, Pages 275-282

  Johansson, Jan ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Alzheimer's disease; Amyloid peptide; Discordant helix; Prion disease; Prion protein; Protein misfolding; SP C; Helix to strand transition

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; LUNG SURFACTANT; POLYMER; POLYPEPTIDE; POLYVALINE; PRION PROTEIN; PROTEIN C; UNCLASSIFIED DRUG; VALINE;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BRAIN SPONGIOSIS; COGNITIVE DEFECT; CORRELATION ANALYSIS; HUMAN; IN VIVO STUDY; INTERSTITIAL LUNG DISEASE; LIPID BILAYER; LUNG ALVEOLUS; MOLECULAR WEIGHT; MORPHOLOGY; MUTATION; OLIGOMERIZATION; PATHOPHYSIOLOGY; POINT MUTATION; PREDICTION; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; PROTEINOSIS; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

EID: 0037815125     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Sipe JD, Cohen AS. History of the amyloid fibril. J Struct Biol 2000;130:88-98.
2. Serpell LC. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 2000;1502:16-30.
3. Sunde M, Blake CCF. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Quart Rev Biophys 1998;31:1-39.
4. Glenner GG. Amyloid deposits and amyloidosis. The β-fibrilloses (first of two parts). N Engl J Med 1980;302:1283-92.
5. Kelly JW. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 1996;6:11-7.
6. Rochet JC, Lansbury PT Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000;10:60-8.
7. Iconomidou VA, Vriend G, Hamodrakas SJ. Amyloid protect the silkmoth oocyte and embryo. FEBS Lett 2000;479:141-5.
8. Kenney JM, Knight D, Wise MJ, Vollrath F. Amyloidogenic nature of spider silk. Eur Z Biochem 2002;269:4159-63.
9. Atwood CS, Martins RN, Smith MA, Perry G. Senile plaque composition and posttranslational modification of amyloid-β peptide and associated proteins. Peptides 2002;23:1343-50.
10. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amylodidosis. Nature 2002;417:254-9.
11. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. 1997;385:787-93.
12. Liemann S, Glockshuber R. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 1999;38:3528-67.
13. Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, et al. NMR solution structure of the human prion protein. Proc. Natl Acad Sci USA 2000;97:145-50.
14. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993;90:10962-6.
15. Barrow CJ, Yasuda A, Kenny PT, Zagorski MG. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol 1992;225:1075-93.
16. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998;8:101-6.
17. Ramirez-Alvarado M, Merkel JS, Regan L. A sytematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2000;97:8979-84.
18. Canet D, Last AM, Tito P, Sunde M, Spencer A, Archer DB, et al. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat Struct Biol 2002;9:308-15.
19. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 1999; 96:3590-4.
20. Fändrich M, Fletcher MA, Dobson CM. Amyloid fibrils from muscle myoglobin. Even an ordinary globular protein can assume a rogue guise if conditions are right. Nature 2001; 410:165-6.
21. Dalal S, Regan L. Understanding the sequence determinants of conformational switching using protein design. Protein Sci 2000;9:1651-9.
22. Tjernberg L, Hosia W, Bark N, Thyberg J, Johansson J. Charge attraction and β propensity are necessary for amyloid fibril formation from tetrapeptides. J Biol Chem 2002;277:43243-6.
23. Reches M, Porat Y, Gazit E. Amyloid fibrils formation by penta- and tetrapeptide fragments of human calcitonin. J Biol Chem 2002;277:35475-80.
24. Tjernberg LO, Callaway DJE, Tjernberg A, Hahne S, Lilliehöök C, Terenius L, et al. A molecular model of Alzheimer amyloid β-peptide fibril formation. J Biol Chem 1999;274: 12619-25.
25. 2-microglobulin. Nat Struct Biol 2002;9:326-31.
26. 2-microglobulin amyloid fibril by H/D exchange. Nat Struct Biol 2002;9:332-6.
27. 2-microglobulin-insights into the mechanism of fibril formation in vitro. J Mol Biol 2003;325:249-57.
28. Creuwels LA, van Golde LM, Haagsman HP. The pulmonary surfactant system: biochemical and clinical aspects. Lung 1997;175:139.
29. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002;347:2141-8.
30. Johansson J. Structure and properties of surfactant protein C. Biochim Biophys Acta 1998;1408:161-72.
31. Pérez-Gil J, Keough KM. Interfacial properties of surfactant proteins. Biochim Biophys Acta 1998;1408:203-17.
32. Bradbury J. Could treatment of neonatal RDS improve further? Lancet 2002;360:394-5.
33. Augusto L, Le Blay K, Auger G, Blanot D, Chaby R. Interaction of bacterial lipopolysaccharide with mouse surfactant protein C inserted into lipid vesicles. Am J Physiol Lung Cell Mol Physiol 2001;281:L776-L785.
34. Augusto AL, Li J, Synguelakis M, Johansson J, Chaby R. Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide. J Biol Chem 2002;277: 23484-92.
35. Augusto AL, Synguelakis M, Johansson J, Pedron T, Girard R, Chaby R. Interaction of pulmonary surfactant protein C with CD 14 and lipopolysaccharide. Infect Immun 2003;71:61-7.
36. Johansson J, Szyperski T, Curstedt T, Wüthrich K. The NMR structure of the pulmonary surfactant-associated polypeptide SP-C in an apolar solvent contains a valyl-rich α-helix. Biochemistry 1994;33:6015-23.
37. Johansson J, Szyperski T, Wüthrich K. Pulmonary surfactant-associated polypeptide SP-C in lipid micelles: CD studies of intact SP-C and NMR secondary structure determination of depalmitoyl-SP-C(1-17). FEBS Lett 1995;362:261-5.
38. Szyperski T, Vandenbussche G, Curstedt T, Ruysschaert JM, Wüthrich K, Johansson J. Pulmonary surfactant-associated polypeptide C in a mixed organic solvent transforms from a monomeric α-helical state into insoluble β-sheet aggregates. Protein Sci 1998;7:2533-40.
39. Kovacs H, Mark AE, Johansson J, van Gunsteren WF. The effect of environment on the stability of an integral membrane helix: molecular dynamics simulations of surfactant protein C in chloroform, methanol and water. J Mol Biol 1995;247: 808-22.
40. Zangi R, Kovacs H, van Gunsteren WF, Johansson J, Mark AE. Free energy barrier estimation of unfolding the α-helical surfactant-associated polypeptide C. Proteins 2001;43:395-402.
41. Gustafsson M, Thyberg J, Näslund J, Eliasson E, Johansson J. Amyloid fibril formation by pulmonary surfactant protein C. FEBS Lett 1999;464:138-42.
42. Nogee LM, Dunbar AE, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573-9.
43. Thomas AQ, Lane K, Phillips IIIJ, Prince M, Markin C, Speer M, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002;165:1322-8.
44. Kabore AF, Wang WJ, Russo SJ, Beers MF. Biosynthesis of surfactant protein C: characterization of aggresome formation by EGFP chimeras containing propeptide mutants lacking conserved cysteine residues. J Cell Sci 2001;114:293-302.
45. Nogee LM. Abnormal expression of surfactant protein C and lung disease. Am J Respir Cell Mol Biol 2002;26:641-4.
46. Wang WJ, Russo SJ, Mulugeta S, Beers MF. Biosynthesis of surfactant protein C (SP-C). Sorting of SP-C proprotein involves homomeric association via a signal anchor domain. J Biol Chem 2002;277:19929-37.
47. Conkright JJ, Na C-L, Weaver TE. Overexpression of surfactant protein-C mature peptide causes neonatal lethality in transgenic mice. Am J Respir Cell Mol Biol 2002;26:85-90.
48. Glasser SW, Burhans MS, Korfhagen TR, Na CL, Sly PD, Ross GF, et al. Altered stability of pulmonary surfactant in SP-C-deficient mice. Proc Natl Acad Sci USA 2001;98:6366-71.
49. Johansson J, Nilsson G, Strömberg R, Robertson B, Jörnvall H, Curstedt T. Secondary structure and biophysical activity of synthetic analogues of the pulmonary surfactant polypeptide SPC. Biochem J 1995;307:535-41.
50. Nilsson G, Gustafsson M, Vandenbussche G, Veldhuizen E, Griffiths WJ, Sjövall J, et al. Synthetic peptide-containing surfactants - Evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. Eur J Biochem 1998;255:116-24.
51. Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J. Prediction of amyloid fibril-forming proteins. J Biol Chem 2001;276:12945-50.
52. Tjernberg LO, Näslund J, Lindqvist F, Johansson J, Karlström AR, Thyberg J, et al. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996;271:8545-8.
53. Janek K, Rothemund S, Gast K, Beyermann M, Zipper J, Fabian H, Bienert M, Krause E. Study of the conformational transition of Ab(1-42) using D-amino acid replacement analogues. Biochemistry 2001;40:5457-63.
54. Hunt JF, Earnest TN, Bousché O, Kalghati K, Reilly K, Horváth C, et al. A biophysical study of integral membrane protein folding. Biochemistry 1997;36:15156-76.
55. Huang Z, Gabriel J-M, Baldwin MA, Fletrerick RJ, Prusiner SB, Cohen F.E. Proposed three-dimensional structure for the cellular prion protein. Proc Natl Acad Sci USA 1994;91:7139-43.
56. Dima RI, Thirumalai D. Exploring the propensities of helices in PrPc to form β sheet using NMR structures and sequence alignments. Biophys J 2002;83:1268-80.
57. Knaus KJ, Morillas M, Swietnicki W, Malone M, Surewicz WK, Yee VE. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat Struct Biol 2001;8:770-4.
58. Jackson GS, Hosszu LLP, Power A, Hill AF, Kenney J, Saibil H, et al. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 1999;283:1935-7.
59. Soto C, Castano EM, Kumar A, Beavis RC, Frangione B. Fibrillogenesis of synthetic amyloid-13 peptides is dependent on their initial secondary structure. Neurosci Lett 1995;200:105-8.
60. Hosia W, Johansson J, Griffiths WJ. Hydrogen/deuterium exchange and aggregation of a poly-valine and a poly-leucine α-helix investigated by matrix-assisted laser desorption ionization mass spectrometry. Mol Cell Proteomics 2002;1:592-7.
61. Baskakov IV, Legname G, Prusiner SB, Cohen FE. Folding of prion protein to its native α-helical conformation is under kinetic control. J Biol Chem 2001;276:19687-90.
62. Chiti F, Taddei N, Baroni F, Capanni C, Stefani M, Ramponi G, Dobson CM. Kinetic partitioning of protein folding and aggregation. Nat Struct Biol 2002;9:137-43.
63. Taddei N, Capanni C, Chiti F, Stefani M, Dobson CM, Ramponi G. Folding and aggregation are selectively influenced by the conformational preferences of the α-helices of muscle acylphosphatase. J Biol Chem 2001;276:37149-54.
64. Ciani B, Hutchinson EG, Sessions RB, Woolfson DN. A designed system for assessing how sequence affects α to β conformational transitions in proteins. J Biol Chem 2002;277: 10150-55.
65. Liu LP, Deber CM. Uncoupling of hydrophobicity and helicity in transmembrane segments. α-Helical propensities of the amino acids in non-polar environments. J Biol Chem 1998;273: 23645-8.
66. Gustafsson M, Griffiths WJ, Furusjö E, Johansson J. The palmitoyl groups of surfactant protein C reduce unfolding into a fibrillogenic intermediate. J Mol Biol 2001;310:937-50.
67. Richardson JS, Richardson DC. Natural β-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc Natl Acad Sci SA 2002;99:2754-9.
68. Wang W, Hecht MH. Rationally designed mutations convert de novo amyloid-like fibrils into monomeric β-sheet proteins. Proc Natl Acad Sci USA 2002;99:2760-5.
69. Weissmann C. Molecular genetics of transmissible spongiform encephalopathies: an introduction. J Toxicol Sci 2002;27:69-77.
70. Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 1998;32:461-93.
71. Wang J, Dickson DW, Trojanowski JQ, Lee VM-Y. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;158: 328-37.
72. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. J Am Med Assoc 2000;283:1571-7.
73. Davis II JN, Chisholm JC. The "amyloid" cascade hypothesis" of AD: decoy or real McCoy? Trends Neurol Sci 1997;20:558-9.
74. Dahlgren KN, Manelli AM, Stine Jr WB, Baker LK, Krafft GA, LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 2002;277:32046-53.
75. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-53.
76. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, et al. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999;274:25945-52.
77. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-9.
78. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The "Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat Neurosci 2001;4:887-93.
79. El-Agnef OMA, Nagala S, Patel BP, Austen BM. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial british dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol 2001;310:157-68.
80. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416: 507-11.
81. Lashuel HA, Hartley DM, Petre BM, Walz T, Lansbury PT Jr. Amyloid pores from pathogenic mutations. Nature 2002;418: 291.
82. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 2002;4:267-75.
83. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano E, Frangione B. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 1998;4:822-6.
84. Soto C, Kindy SM, Baumann M, Frangione B. Inhibition of Alzheimer's disease amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun 1996;226: 672-80.
85. Chiti F, Taddei N, Stefani M, Dobson CM, Ramponi G. Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. Protein Sci 2001;10: 879-86.
86. Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA 1998;95:12956-60.
87. Voss T, Schäfer KP, Nielsen PF, Schäfer A, Maier C, Hannappel E, et al. Primary structure differences of human surfactant-associated proteins isolated from normal and proteinosis lung. Biochim Biophys Acta 1992;1138:261-7.
88. Fezoui Y, Teplow DB. Kinetic studies of amyloid β-protein fibril assembly: Differential effects of α-helix stabilization. J Biol Chem 2002;277:36948-54.
89. Kirkitadze MD, Condron MM. Teplow DB. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis. J Mol Biol 2001;312:1103-19.